Cargando…

Cardiotoxicity of Non-Anthracycline Cancer Chemotherapy Agents

Throughout the last decades, newly developed chemotherapeutic agents and immunotherapies that target signaling pathways have provided patients with better prognoses, improved their quality of life and increased survival rates, thus converting cancer to a stable chronic disease. However, non-anthracy...

Descripción completa

Detalles Bibliográficos
Autores principales: Briasoulis, Alexandros, Chasouraki, Angeliki, Sianis, Alexandros, Panagiotou, Nikolaos, Kourek, Christos, Ntalianis, Argyrios, Paraskevaidis, Ioannis
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8953347/
https://www.ncbi.nlm.nih.gov/pubmed/35323614
http://dx.doi.org/10.3390/jcdd9030066
_version_ 1784675828471169024
author Briasoulis, Alexandros
Chasouraki, Angeliki
Sianis, Alexandros
Panagiotou, Nikolaos
Kourek, Christos
Ntalianis, Argyrios
Paraskevaidis, Ioannis
author_facet Briasoulis, Alexandros
Chasouraki, Angeliki
Sianis, Alexandros
Panagiotou, Nikolaos
Kourek, Christos
Ntalianis, Argyrios
Paraskevaidis, Ioannis
author_sort Briasoulis, Alexandros
collection PubMed
description Throughout the last decades, newly developed chemotherapeutic agents and immunotherapies that target signaling pathways have provided patients with better prognoses, improved their quality of life and increased survival rates, thus converting cancer to a stable chronic disease. However, non-anthracycline cancer chemotherapy agents and immunotherapies including human epidermal growth factor receptor 2 (HER2) inhibitors, vascular endothelial growth factor (VEGF) inhibitors, Bcr-Abl tyrosine-kinase inhibitors (TKI), proteasome inhibitors, immune checkpoint inhibitors and chimeric antigen receptor T cells (CAR-T cells) may cause cardiovascular toxicity events and complications that usually interrupt the continuation of an appropriate treatment regimen, which induces life-threatening risks or leads to long-term morbidity. Heart failure, cardiac arrythmias and cardiomyopathies are the most common cardiovascular events related to cardiotoxicity due to chemotherapy. Each patient should be carefully assessed and monitored before, during and after the administration of chemotherapy, to address any predisposing risk factors and the new onset of cardiotoxicity manifestations early and treat them appropriately. The development of novel anticancer agents that cause minimal cardiovascular toxicity events or novel agents that ameliorate the adverse effects of the existing anticancer agents could drastically change the field of cardio-oncology. The aim of this narrative review is to demonstrate new knowledge regarding the screening and diagnosis of non-anthracycline-induced cardiotoxicity and to propose protective measures that could be performed in order to achieve the delivery of optimal care.
format Online
Article
Text
id pubmed-8953347
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-89533472022-03-26 Cardiotoxicity of Non-Anthracycline Cancer Chemotherapy Agents Briasoulis, Alexandros Chasouraki, Angeliki Sianis, Alexandros Panagiotou, Nikolaos Kourek, Christos Ntalianis, Argyrios Paraskevaidis, Ioannis J Cardiovasc Dev Dis Review Throughout the last decades, newly developed chemotherapeutic agents and immunotherapies that target signaling pathways have provided patients with better prognoses, improved their quality of life and increased survival rates, thus converting cancer to a stable chronic disease. However, non-anthracycline cancer chemotherapy agents and immunotherapies including human epidermal growth factor receptor 2 (HER2) inhibitors, vascular endothelial growth factor (VEGF) inhibitors, Bcr-Abl tyrosine-kinase inhibitors (TKI), proteasome inhibitors, immune checkpoint inhibitors and chimeric antigen receptor T cells (CAR-T cells) may cause cardiovascular toxicity events and complications that usually interrupt the continuation of an appropriate treatment regimen, which induces life-threatening risks or leads to long-term morbidity. Heart failure, cardiac arrythmias and cardiomyopathies are the most common cardiovascular events related to cardiotoxicity due to chemotherapy. Each patient should be carefully assessed and monitored before, during and after the administration of chemotherapy, to address any predisposing risk factors and the new onset of cardiotoxicity manifestations early and treat them appropriately. The development of novel anticancer agents that cause minimal cardiovascular toxicity events or novel agents that ameliorate the adverse effects of the existing anticancer agents could drastically change the field of cardio-oncology. The aim of this narrative review is to demonstrate new knowledge regarding the screening and diagnosis of non-anthracycline-induced cardiotoxicity and to propose protective measures that could be performed in order to achieve the delivery of optimal care. MDPI 2022-02-23 /pmc/articles/PMC8953347/ /pubmed/35323614 http://dx.doi.org/10.3390/jcdd9030066 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Review
Briasoulis, Alexandros
Chasouraki, Angeliki
Sianis, Alexandros
Panagiotou, Nikolaos
Kourek, Christos
Ntalianis, Argyrios
Paraskevaidis, Ioannis
Cardiotoxicity of Non-Anthracycline Cancer Chemotherapy Agents
title Cardiotoxicity of Non-Anthracycline Cancer Chemotherapy Agents
title_full Cardiotoxicity of Non-Anthracycline Cancer Chemotherapy Agents
title_fullStr Cardiotoxicity of Non-Anthracycline Cancer Chemotherapy Agents
title_full_unstemmed Cardiotoxicity of Non-Anthracycline Cancer Chemotherapy Agents
title_short Cardiotoxicity of Non-Anthracycline Cancer Chemotherapy Agents
title_sort cardiotoxicity of non-anthracycline cancer chemotherapy agents
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8953347/
https://www.ncbi.nlm.nih.gov/pubmed/35323614
http://dx.doi.org/10.3390/jcdd9030066
work_keys_str_mv AT briasoulisalexandros cardiotoxicityofnonanthracyclinecancerchemotherapyagents
AT chasourakiangeliki cardiotoxicityofnonanthracyclinecancerchemotherapyagents
AT sianisalexandros cardiotoxicityofnonanthracyclinecancerchemotherapyagents
AT panagiotounikolaos cardiotoxicityofnonanthracyclinecancerchemotherapyagents
AT kourekchristos cardiotoxicityofnonanthracyclinecancerchemotherapyagents
AT ntalianisargyrios cardiotoxicityofnonanthracyclinecancerchemotherapyagents
AT paraskevaidisioannis cardiotoxicityofnonanthracyclinecancerchemotherapyagents